Leerink lowered the firm’s price target on Ardent Health (ARDT) to $15 from $16 and keeps an Outperform rating on the shares. The firm says the company’s Q4 results were better than last quarter with stabilization in payer denials and professional fees, solid volumes, and good expense management. Leerink believes the shares are trading at an “overly harsh” valuation given Ardent’s growth prospects.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $13 from $14 at UBS
- Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating
- Underperform Reiterated on Ardent: Aggressive EBITDA Targets and Reimbursement Risks Undermine Valuation
- Ardent Health reports Q4 EPS 32c, consensus 35c
- Ardent Health sees FY26 EPS $0.90-$1.27, consensus $1.35